Every Peptide

The next oral peptide story is an immune drug

Icotrokinra, the FDA-approved oral peptide IL-23 receptor antagonist for plaque psoriasis, shows how peptide pills are moving from metabolic medicine into immunology.

Research Updates By Every Peptide Editorial Team

The peptide-pill story is starting to look less like a weight-loss subplot and more like a platform shift.

Icotrokinra, sold as ICOTYDE, is an oral peptide drug that blocks the interleukin-23 receptor, a major immune target in plaque psoriasis. The Food and Drug Administration label lists it for moderate-to-severe plaque psoriasis in adults and adolescents 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. That makes it more than another dermatology launch. It is a real-world test of whether a peptide can behave like the kind of convenient daily pill patients and clinicians already understand, while aiming at biology more commonly associated with injectable biologics.

That is the interesting implication. Icotrokinra is not trying to be a better GLP-1. It is trying to pull a biologic-style immune target into oral chronic treatment.

Why this matters beyond psoriasis

Modern psoriasis treatment changed when injectable biologics made deep skin clearance plausible by targeting immune pathways such as interleukin-17 and interleukin-23. For many patients, those drugs can be powerful. But injections, refrigeration, insurance hurdles, specialty-pharmacy logistics, and patient preference still shape how treatment actually happens.

An oral IL-23 pathway drug changes the framing. If the efficacy is close enough and the safety profile holds up over time, the question becomes less “can we make immune drugs work?” and more “which immune targets can be turned into high-specificity pills?”

That matters for peptides because they sit in a useful middle ground. They can sometimes reach protein-protein interaction surfaces that are awkward for conventional small molecules, but they are usually harder to deliver by mouth. Icotrokinra is a reminder that this boundary is moving: oral peptides are no longer only about gut hormones or metabolic disease.

The clinical signal is unusually concrete

The strongest evidence comes from phase 3 plaque psoriasis trials.

In the ICONIC-LEAD trial published in The New England Journal of Medicine, 684 adults and adolescents with moderate-to-severe plaque psoriasis were assigned to icotrokinra or placebo. At week 16, 65% of participants receiving icotrokinra had clear or almost clear skin on the Investigator’s Global Assessment, compared with 8% on placebo. Half of the icotrokinra group reached PASI 90, meaning at least a 90% reduction in Psoriasis Area and Severity Index score, compared with 4% on placebo. Adverse-event rates through week 16 were 49% in both groups.

Two active-comparator phase 3 trials published in The Lancet added another useful comparison. In ICONIC-ADVANCE 1 and 2, icotrokinra beat placebo on the same week-16 clearance measures and also showed higher response rates than the oral TYK2 inhibitor deucravacitinib in the trial reports. Across the two studies, adverse events through week 16 occurred in 48% of icotrokinra-treated participants and 57% of placebo-treated participants; through week 24, adverse-event rates were reported as lower with icotrokinra than with deucravacitinib.

A newer meta-analysis pulled together five randomized trials and found the same broad pattern: higher rates of clear or almost clear skin and PASI 90 with icotrokinra than placebo, with no new short-term safety signal over the 16-week trial windows.

Those numbers make the story easier to understand. This is not just a clever formulation paper. It is an approved oral peptide with randomized human data in a common chronic inflammatory disease.

The caveat: short-term success is not the whole story

The responsible reading is not that oral peptides will replace injectable biologics.

Psoriasis is a long-term disease, and immune modulation is judged over years, not only 16 weeks. The published trials and meta-analyses are encouraging, but longer follow-up, broader real-world use, rare adverse events, persistence, adherence, and payer behavior will matter. A patient who does well in a controlled trial is not the same as a patient navigating refills, comorbidities, missed doses, drug interactions, and insurance step therapy.

There is also a category-level question. Icotrokinra may have the right combination of potency, selectivity, stability, absorption, and target biology. That does not mean the same trick will work for every cytokine pathway or every immune disease.

Still, exceptions can become templates. Semaglutide helped normalize the idea that a peptide could be a mass-market chronic medicine. Enlicitide is testing whether a macrocyclic peptide can become a cardiovascular pill. Icotrokinra extends the point into immunology.

The real shift is patient expectations

The most human consequence is simple: some patients who would have faced a choice between topical therapy, older systemic drugs, and injectable biologics may now see an oral targeted option in the conversation.

That does not make the decision automatic. Dermatologists will still weigh severity, prior treatment, pregnancy plans, infection risk, comorbidities, cost, and patient preference. But treatment categories shape expectations. Once a high-specificity immune therapy becomes a pill, people start asking why more of them cannot be pills too.

That is where icotrokinra matters most for the peptide field. It turns “oral peptide delivery” from a technical aspiration into a patient-facing category: not just can the molecule survive the gut, but can it change how chronic specialty diseases are treated?

The unresolved question is whether this is the beginning of a broader oral-peptide immunology era or a highly optimized one-off. The answer will depend less on the launch headline than on what happens next: long-term safety, real-world adherence, comparative effectiveness, access, and whether other peptide companies can repeat the formula against targets patients actually care about.

Further reading

Related reading

  • The oral peptide story is moving beyond weight loss

    Enlicitide, an oral macrocyclic peptide PCSK9 inhibitor, is turning cholesterol treatment into a test case for whether complex peptides can become everyday pills.

  • A tiny amino acid tweak that can help peptides go oral

    A medicinal-chemistry study suggests one residue, Aib, can sometimes ‘pre-organize’ macrocyclic peptides so they cross membranes more easily, improving oral exposure in mice. It is scaffold-dependent, not magic.

  • A beta cell-targeted PD‑1 agonist for type 1 diabetes

    A Science Advances paper describes a bispecific ‘ImmTAAI’ molecule that binds a preproinsulin peptide–HLA complex on beta cells and delivers a PD‑1 agonist signal to suppress autoreactive T cells locally in human pancreas slice models. It’s early, but it’s an unusually concrete example of tissue-targeted immunomodulation in type 1 diabetes.

  • Why SNAC’s chemistry may be the hidden variable in oral peptide pills

    A new mechanistic study shows SNAC, the absorption enhancer used in oral semaglutide, changes state with pH, salts, bile, and co-medications—conditions that may shape oral peptide consistency.

Explore more

NewsOral deliveryImmunologyPsoriasisMacrocyclic peptidesRegulatory